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Effects of the triphosphates of eight pyrimidine nucleoside analogs (5-substitut-
ed, 2'-fluoroara-, and acyclonucleosides) and acycloguanosine were examined on
the ribonucleotide reductases prepared from uninfected and herpes simplex virus
(types 1 and 2)-infected HeLa cells. Of the analogs tested, E-5-propenyl- and E-5-
(2-bromovinyl)-dUTP were more potent inhibitors than dTTP of the enzymes
from virus-infected cells, whereas only the former compound showed this effect
on the uninfected HeLa enzyme.
Ribonucleotide reductase (EC 1.17.4.1) from
eucaryotic cells catalyzes the reduction of ribo-
nucleoside diphosphates to 2'-deoxynucleoside
diphosphates, similar to the Escherichia coli
enzyme which has been extensively studied (12).
This enzyme, which is involved in a balanced
formation ofdCDP, dUDP, dGDP, and dADP, is
allosterically regulated in a complex manner by
ribo- and deoxyribonucleoside triphosphates.
Since the pathways involving ribonucleotide re-
ductase comprise the major de novo source of
four deoxynucleoside triphosphates for DNA
synthesis, and since intracellular deoxynucleo-
side triphosphate pools are usually too small to
sustain DNA synthesis for more than a few
minutes, the possibility of influencing the en-
zyme has implications in both antiviral and
antineoplastic chemotherapy. Close correlations
have been observed between rate of tumor
growth and amount of reductase activity (6).
Other groups (8, 9) have reported three- to
ninefold increases in reductase activity after
infection with herpes simplex virus (HSV). The
enzyme specificity in HSV-infected cells also
differs in regulatory response to dTTP and dATP
from uninfected cells (8, 9), although there is no
direct evidence which indicates the virus-in-
duced ribonucleotide reductase activity is actu-
ally encoded on the viral genome.
We extracted the reductase activity from
HeLa cells, HSV type 1 (HSV-1)-infected HeLa
cells, and HSV-2-infected cells and examined
the behavior of the triphosphates of acycloguan-
osine (7), E-5-(2-bromovinyl)-2'-deoxyuridine
(BV-dUrd) (5), 2'-fluoro-5-iodo-1-j3-D-arabino-
cytosine (FIAC) (13), E-5-propenyl-2'-deoxyuri-
dine (propenyl-dUrd) (4), and several other ana-
logs on the enzyme preparations. Assessing any
effects of the analog nucleoside triphosphates on
ribonucleotide reductase could prove useful,
since the molecular site of the antiviral-antican-
cer action is still unclear for the nucleoside
analogs.
Analog triphosphates were chemically synthe-
sized by a general procedure described earlier
(11) and were greater than 96% homogeneous
upon anion-exchange high-pressure liquid chro-
matography. Ribonucleotide reductase prepara-
tions were obtained by a modification of the
method of Ponce de Leon et al. (10): HeLa S3
cells grown in suspension were either uninfected
or infected with HSV-1 (KOS) or HSV-2 (333) at
5 to 10 PFU per cell for 10 h. Cell pellets were
disrupted in 5 volumes of homogenizing buffer
(50 mM HEPES [N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid] buffer [pH 7.5], 2 mM
dithiothreitol, 1 mM MgCl2) by using a glass
homogenizer and then centrifuged for 30 min at
20,000 x g. Streptomycin sulfate (final concen-
tration, 1%) was added to the supematant. After
centrifugation, ammonium sulfate (45% satura-
tion) was added to the supernatant. The precipi-
tate which formed was collected by centrifuga-
tion, dissolved in homogenizing buffer, dialyzed
against additional buffer, and used as the en-
zyme. Purification of ribonucleotide reductase
to high purity was not accomplished since at-
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FIG. 1. Effect of dUTP analogs on CDP reduction.
Enzyme was prepared from (A) mock-, (B) HSV-1-,
and (C) HSV-2-infected HeLa cells. CDP reduction is
expressed as the percentage of dCDP formation in the
control. Symbols: (0) dTTP; (0) 5-propyl-dUTP; (A)
E-5-propenyl-dUTP; (A) E-5-(2-bromovinyl)-dUTP.
activity. This lability of virus-induced reduc-
tases has been observed by others (8). Although
it is unlikely that the host enzyme exists for 10 h
postinfection without any modification (1), it is
not clear to what degree the reductase activity
obtained from HSV-infected cells reflects true
virus-induced activity. Therefore, the data pre-
sented here should be considered preliminary
pending further purification and characterization
of the enzymes.
Ribonucleotide reductase assays, at 0.1 scale,
were performed as described earlier (2, 3), using
[2-14CjCDP.
The enzymatic reduction of CDP to dCDP is
allosterically inhibited by dTTP, dGTP, and
dATP (3, 12). By using the crude enzyme prepa-
rations described above, it was found that ribo-
nucleotide reductase from either HSV-1- or
HSV-2-infected cells was less sensitive to inhibi-
tion by dTTP and dGTP than was the enzyme
from uninfected HeLa cells and equally sensi-
tive to inhibition by dATP. These observations
are in partial agreement with other studies,
which have reported that reductases from HSV-
1-infected KB cells (10) and HSV-infected Vero
cells (9) are less sensitive to both dTTP and
dATP.
With formation of dCDP from CDP as a
measure of reductase activity, the triphosphates
of three selective antiviral 5-substituted nucleo-
sides were tested as allosteric inhibitors of the
enzyme and compared with dTTP (Table 1; Fig.
1). E-5-Propenyl-dUTP was more inhibitory
than dTTP for all three enzyme preparations. E-
5-(2-Bromovinyl)-dUTP had less effect than
dTTP on reductase from uninfected cells but
was more inhibitory than dTTP on enzymes
from either HSV-1- or HSV-2-infected cells. 5-
Propyl-dUTP was a very poor inhibitor (50 >
400 ,uM) of all of the enzyme preparations. (I50 is
the concentration inhibiting the reduction of
CDP by 50%, relative to control.)
Several 2'-deoxy-2'-fluoroarabinoside and
acyclonucleoside triphosphates were also tested
as inhibitors of CDP reduction (Table 1). The
triphosphate of FIAC was a very poor inhibitor
(Iso, 360 to 720 ,uM) of reductase activity, al-
though it was slightly more effective against the
reductase from HSV-infected cells. Both 2'-
fluoro-araTTP and 2'-fluoro-5-methyl-araCTP
were mild inhibitors. Acyclo-GTP, acyclo-CTP,
and acyclo-TTP were also poor inhibitors (I50 >
200 i,M) of all of the ribonucleotide reductase
preparations.
Several of these nucleoside analogs are potent
TABLE 1. Effect of nucleoside triphosphate analogs
on ribonucleotide reductase
I50a (>M)
Inhibitor Mock HSV-1 HSV-2
in- in- in-
fected fected fected
dTTP 45 88 220
5-Propyl-dUTP >400 >400 >400
E-5-Propenyl-dUTP 18 56 92
E-5-(2-Bromovinyl)-dUTP 95 49 66
2'-Fluoro-araTTP 80 175 160
2'-Fluoro-5-iodo-araCTP 730 430 360
2'-Fluoro-5-methyl-araCTP 175 235 160
Acyclo-TTPb >200 NDC ND
Acyclo-CTPb 200 ND ND
Acyclo-GTPb >200 >200 >200
a Io represents the concentration of a drug which
inhibited the reduction of CDP by 509%, relative to
control (mean of duplicates).
b Acyclonucleotides refer to analogs in which the
sugar moieties are replaced by a (2-hydroxy-
ethoxy)methyl group.
c ND, Not determined.
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and quite selective antiviral agents, especially
BV-dUrd, acycloguanosine, FIAC, propenyl-
dUrd, and propyl-dUrd. Most of them depend
on phosphorylation by the HSV-encoded thymi-
dine kinase for their selectivity (4, 7, 11). Al-
though it appears that these analogs exert viru-
cidal action after phosphorylation, the actual
sites of the action are still unclear. The results
presented here strongly suggest that the antiviral
activities for the analogs, including propyl-
dUrd, acycloguanosine, and FIAC, cannot be
mediated to any significant extent through ribo-
nucleotide reductase. However, the triphos-
phates of propenyl-dUrd and BV-dUrd appear
to exert a significant effect on the ribonucleotide
reductases, a factor which could contribute to
the overall antiviral activities of the two analogs.
In particular, BV-dUTP showed more inhibitory
effect on reductase from HSV-infected cells than
on that from uninfected cells, in contrast with E-
5-propenyl-dUTP and dTTP. Based on the ap-
parent differences in response to the analog
triphosphates, ribonucleotide reductases from
HSV-1-and HSV-2-infected cells are similar to
each other, and both exhibit altered specificity
from the enzyme in uninfected cells.
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